Recent insider selling at Denali Therapeutics Inc (DNLI) has drawn renewed attention from investors. On August 12, 2025, Schuth Alexander O. sold 2,937 shares at $13.58 each, totaling $39,884. After the sale, his holdings dropped to 242,346 shares valued at about $4.7 million.
Another insider, Ho Carole, also sold 2,937 shares for the same total amount at the same price, reducing her position to 217,391 shares. Prior to that, she sold 806 shares at $14.64 each in a transaction valued at $11,800. After the sale, her remaining holdings—valued at roughly $4.2 million—reflected a continued trimming of insider positions. These repeated sales have sparked speculation regarding insider expectations.
Street Opinions Shift
Analyst sentiment for DNLI has been improving. Cantor Fitzgerald upgraded the stock from Neutral to Overweight on April 10, 2025. Deutsche Bank began coverage with a Buy rating in February 2025, while Robert W. Baird initiated with an Outperform recommendation in early January. The trend suggests growing confidence in the company’s clinical pipeline and long-term trajectory.
Market Momentum Builds
In the most recent session, DNLI climbed 1.41% to close at $19.40. The stock moved between $18.74 and $19.575 throughout the day. Over the past week, shares have surged 14.66%, although they remain down 21.43% year-to-date. Denali’s 52-week range spans a high of $24.34 on February 5, 2025, and a low of $10.57 on April 7, 2025.
Key Price Levels to Watch
Charts show immediate support at 18.90. If this area fails, prices could fall toward 18.40. On the upside, resistance sits at 19.74, with a second barrier at 20.07. The 14-day RSI stands at 70.58, indicating overbought conditions and suggesting potential volatility ahead.
Short Interest Trends
Short interest saw a notable drop on November 14, 2025, declining by 0.51 million shares to 14.02 million. Compared with 14.53 million on October 15, this reflects a 3.64% decline, signaling improved sentiment among bearish traders. Short positions represent about 8.88% of the float, with the days-to-cover ratio also at 8.88.
Who Holds the Most?
Analysts tracked by FactSet project an average 12-month price target of 37, forecasting an impressive 93.41% upside from the prior close of $19.13. Forecasts uniformly point to 37 as the expected price in 2025. By the end of 2025, four analysts rated DNLI as a Buy, showing growing optimism despite recent insider sales.
